VP22 enhances antibody responses from DNA vaccines but not by intercellular spread
In some species DNA vaccines elicit potent humoral and cellular immune responses. However, their performance in humans and non-human primates is less impressive. There are suggestions in the literature that an increase in the intercellular distribution of protein expressed from a DNA vaccine may enh...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2005-03, Vol.23 (16), p.1931-1940 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1940 |
|---|---|
| container_issue | 16 |
| container_start_page | 1931 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Perkins, Stuart D. Hartley, M. Gill Lukaszewski, Roman A. Phillpotts, Robert J. Stevenson, Freda K. Bennett, Alice M. |
| description | In some species DNA vaccines elicit potent humoral and cellular immune responses. However, their performance in humans and non-human primates is less impressive. There are suggestions in the literature that an increase in the intercellular distribution of protein expressed from a DNA vaccine may enhance immunogenicity. We incorporated the Herpes Simplex Virus type 1 (HSV) VP22 gene, which encodes a protein that has been described as promoting intercellular spread, into a DNA vector in which it was fused to enhanced green fluorescent protein (EGFP). Following transfection of the plasmid DNA into mammalian cells, distribution of the fusion protein VP22-EGFP was not increased compared to EGFP alone. Furthermore, we found no evidence to suggest that VP22 was capable of mediating intercellular spread. However, when these constructs were used as DNA vaccines to immunise mice, antibody levels specific to EGFP were significantly enhanced when EGFP was fused to VP22. These data suggest that amplification of the immune response may occur via mechanisms other than VP22-mediated intercellular spread of antigen. |
| doi_str_mv | 10.1016/j.vaccine.2004.10.033 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67471013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04007819</els_id><sourcerecordid>67471013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-6a1d1f2c898938e4a7107c0e57c7173bdfcec1aa6b278b3d7c9eb7c9f4d0bd853</originalsourceid><addsrcrecordid>eNqFkVuLFDEQRoMo7rj6E5SA6FuPqVw66SdZ1issKqLiW8ilGjP0dI9J98L8ezNMw4Iv-5JAcepLpQ4hz4FtgUH7Zre9dSGkEbecMVlrWybEA7IBo0XDFZiHZMN4KxsJ7PcFeVLKjjGmBHSPyQUoLSRr1YZ8__WNc4rjHzcGLNSNc_JTPNKM5TCNpZb6PO3puy9XdH2vUL_MdJxm6o80jTPmgMOwDC7Tcsjo4lPyqHdDwWfrfUl-fnj_4_pTc_P14-frq5smSMXnpnUQoefBdKYTBqXTwHRgqHTQoIWPfcAAzrWea-NF1KFDX49eRuajUeKSvD7nHvL0d8Ey230qp1nciNNSbKtljQRxLwjaCA66reDL_8DdtOSxfsKCUh3TvJOmUupMhTyVkrG3h5z2Lh8tMHtyY3d23ZU9uTmVq5va92JNX_we413XKqMCr1bAleCGPlcnqdxxWpkORFe5t2cO63ZvE2ZbQsLqL6aMYbZxSveM8g-oXa6h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559072948</pqid></control><display><type>article</type><title>VP22 enhances antibody responses from DNA vaccines but not by intercellular spread</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Perkins, Stuart D. ; Hartley, M. Gill ; Lukaszewski, Roman A. ; Phillpotts, Robert J. ; Stevenson, Freda K. ; Bennett, Alice M.</creator><creatorcontrib>Perkins, Stuart D. ; Hartley, M. Gill ; Lukaszewski, Roman A. ; Phillpotts, Robert J. ; Stevenson, Freda K. ; Bennett, Alice M.</creatorcontrib><description>In some species DNA vaccines elicit potent humoral and cellular immune responses. However, their performance in humans and non-human primates is less impressive. There are suggestions in the literature that an increase in the intercellular distribution of protein expressed from a DNA vaccine may enhance immunogenicity. We incorporated the Herpes Simplex Virus type 1 (HSV) VP22 gene, which encodes a protein that has been described as promoting intercellular spread, into a DNA vector in which it was fused to enhanced green fluorescent protein (EGFP). Following transfection of the plasmid DNA into mammalian cells, distribution of the fusion protein VP22-EGFP was not increased compared to EGFP alone. Furthermore, we found no evidence to suggest that VP22 was capable of mediating intercellular spread. However, when these constructs were used as DNA vaccines to immunise mice, antibody levels specific to EGFP were significantly enhanced when EGFP was fused to VP22. These data suggest that amplification of the immune response may occur via mechanisms other than VP22-mediated intercellular spread of antigen.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.10.033</identifier><identifier>PMID: 15734065</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic ; Amino acids ; Animals ; Antibody Formation - drug effects ; Antigens ; Applied microbiology ; Biological and medical sciences ; Blotting, Western ; Cercopithecus aethiops ; COS Cells ; Deoxyribonucleic acid ; DNA ; DNA vaccine ; Fundamental and applied biological sciences. Psychology ; GFP ; Green Fluorescent Proteins - immunology ; Herpes simplex virus 1 ; Immune response ; Immunization ; Immunogenicity ; Intercellular spread ; Kinases ; Laboratories ; Methanol ; Mice ; Mice, Inbred BALB C ; Microbiology ; Plasmids - immunology ; Primates ; Protein transduction domain ; Proteins ; Studies ; Tissue Fixation ; Transfection ; Tumors ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, DNA - immunology ; Viral Fusion Proteins - pharmacology ; Viral Structural Proteins - pharmacology ; VP22</subject><ispartof>Vaccine, 2005-03, Vol.23 (16), p.1931-1940</ispartof><rights>2004 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Limited Mar 14, 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-6a1d1f2c898938e4a7107c0e57c7173bdfcec1aa6b278b3d7c9eb7c9f4d0bd853</citedby><cites>FETCH-LOGICAL-c452t-6a1d1f2c898938e4a7107c0e57c7173bdfcec1aa6b278b3d7c9eb7c9f4d0bd853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559072948?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17589139$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15734065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perkins, Stuart D.</creatorcontrib><creatorcontrib>Hartley, M. Gill</creatorcontrib><creatorcontrib>Lukaszewski, Roman A.</creatorcontrib><creatorcontrib>Phillpotts, Robert J.</creatorcontrib><creatorcontrib>Stevenson, Freda K.</creatorcontrib><creatorcontrib>Bennett, Alice M.</creatorcontrib><title>VP22 enhances antibody responses from DNA vaccines but not by intercellular spread</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In some species DNA vaccines elicit potent humoral and cellular immune responses. However, their performance in humans and non-human primates is less impressive. There are suggestions in the literature that an increase in the intercellular distribution of protein expressed from a DNA vaccine may enhance immunogenicity. We incorporated the Herpes Simplex Virus type 1 (HSV) VP22 gene, which encodes a protein that has been described as promoting intercellular spread, into a DNA vector in which it was fused to enhanced green fluorescent protein (EGFP). Following transfection of the plasmid DNA into mammalian cells, distribution of the fusion protein VP22-EGFP was not increased compared to EGFP alone. Furthermore, we found no evidence to suggest that VP22 was capable of mediating intercellular spread. However, when these constructs were used as DNA vaccines to immunise mice, antibody levels specific to EGFP were significantly enhanced when EGFP was fused to VP22. These data suggest that amplification of the immune response may occur via mechanisms other than VP22-mediated intercellular spread of antigen.</description><subject>Adjuvants, Immunologic</subject><subject>Amino acids</subject><subject>Animals</subject><subject>Antibody Formation - drug effects</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Cercopithecus aethiops</subject><subject>COS Cells</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA vaccine</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>GFP</subject><subject>Green Fluorescent Proteins - immunology</subject><subject>Herpes simplex virus 1</subject><subject>Immune response</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Intercellular spread</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Methanol</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Plasmids - immunology</subject><subject>Primates</subject><subject>Protein transduction domain</subject><subject>Proteins</subject><subject>Studies</subject><subject>Tissue Fixation</subject><subject>Transfection</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, DNA - immunology</subject><subject>Viral Fusion Proteins - pharmacology</subject><subject>Viral Structural Proteins - pharmacology</subject><subject>VP22</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkVuLFDEQRoMo7rj6E5SA6FuPqVw66SdZ1issKqLiW8ilGjP0dI9J98L8ezNMw4Iv-5JAcepLpQ4hz4FtgUH7Zre9dSGkEbecMVlrWybEA7IBo0XDFZiHZMN4KxsJ7PcFeVLKjjGmBHSPyQUoLSRr1YZ8__WNc4rjHzcGLNSNc_JTPNKM5TCNpZb6PO3puy9XdH2vUL_MdJxm6o80jTPmgMOwDC7Tcsjo4lPyqHdDwWfrfUl-fnj_4_pTc_P14-frq5smSMXnpnUQoefBdKYTBqXTwHRgqHTQoIWPfcAAzrWea-NF1KFDX49eRuajUeKSvD7nHvL0d8Ey230qp1nciNNSbKtljQRxLwjaCA66reDL_8DdtOSxfsKCUh3TvJOmUupMhTyVkrG3h5z2Lh8tMHtyY3d23ZU9uTmVq5va92JNX_we413XKqMCr1bAleCGPlcnqdxxWpkORFe5t2cO63ZvE2ZbQsLqL6aMYbZxSveM8g-oXa6h</recordid><startdate>20050314</startdate><enddate>20050314</enddate><creator>Perkins, Stuart D.</creator><creator>Hartley, M. Gill</creator><creator>Lukaszewski, Roman A.</creator><creator>Phillpotts, Robert J.</creator><creator>Stevenson, Freda K.</creator><creator>Bennett, Alice M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050314</creationdate><title>VP22 enhances antibody responses from DNA vaccines but not by intercellular spread</title><author>Perkins, Stuart D. ; Hartley, M. Gill ; Lukaszewski, Roman A. ; Phillpotts, Robert J. ; Stevenson, Freda K. ; Bennett, Alice M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-6a1d1f2c898938e4a7107c0e57c7173bdfcec1aa6b278b3d7c9eb7c9f4d0bd853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adjuvants, Immunologic</topic><topic>Amino acids</topic><topic>Animals</topic><topic>Antibody Formation - drug effects</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Cercopithecus aethiops</topic><topic>COS Cells</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA vaccine</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>GFP</topic><topic>Green Fluorescent Proteins - immunology</topic><topic>Herpes simplex virus 1</topic><topic>Immune response</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Intercellular spread</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Methanol</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Plasmids - immunology</topic><topic>Primates</topic><topic>Protein transduction domain</topic><topic>Proteins</topic><topic>Studies</topic><topic>Tissue Fixation</topic><topic>Transfection</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, DNA - immunology</topic><topic>Viral Fusion Proteins - pharmacology</topic><topic>Viral Structural Proteins - pharmacology</topic><topic>VP22</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perkins, Stuart D.</creatorcontrib><creatorcontrib>Hartley, M. Gill</creatorcontrib><creatorcontrib>Lukaszewski, Roman A.</creatorcontrib><creatorcontrib>Phillpotts, Robert J.</creatorcontrib><creatorcontrib>Stevenson, Freda K.</creatorcontrib><creatorcontrib>Bennett, Alice M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perkins, Stuart D.</au><au>Hartley, M. Gill</au><au>Lukaszewski, Roman A.</au><au>Phillpotts, Robert J.</au><au>Stevenson, Freda K.</au><au>Bennett, Alice M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VP22 enhances antibody responses from DNA vaccines but not by intercellular spread</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2005-03-14</date><risdate>2005</risdate><volume>23</volume><issue>16</issue><spage>1931</spage><epage>1940</epage><pages>1931-1940</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>In some species DNA vaccines elicit potent humoral and cellular immune responses. However, their performance in humans and non-human primates is less impressive. There are suggestions in the literature that an increase in the intercellular distribution of protein expressed from a DNA vaccine may enhance immunogenicity. We incorporated the Herpes Simplex Virus type 1 (HSV) VP22 gene, which encodes a protein that has been described as promoting intercellular spread, into a DNA vector in which it was fused to enhanced green fluorescent protein (EGFP). Following transfection of the plasmid DNA into mammalian cells, distribution of the fusion protein VP22-EGFP was not increased compared to EGFP alone. Furthermore, we found no evidence to suggest that VP22 was capable of mediating intercellular spread. However, when these constructs were used as DNA vaccines to immunise mice, antibody levels specific to EGFP were significantly enhanced when EGFP was fused to VP22. These data suggest that amplification of the immune response may occur via mechanisms other than VP22-mediated intercellular spread of antigen.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15734065</pmid><doi>10.1016/j.vaccine.2004.10.033</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2005-03, Vol.23 (16), p.1931-1940 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67471013 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Adjuvants, Immunologic Amino acids Animals Antibody Formation - drug effects Antigens Applied microbiology Biological and medical sciences Blotting, Western Cercopithecus aethiops COS Cells Deoxyribonucleic acid DNA DNA vaccine Fundamental and applied biological sciences. Psychology GFP Green Fluorescent Proteins - immunology Herpes simplex virus 1 Immune response Immunization Immunogenicity Intercellular spread Kinases Laboratories Methanol Mice Mice, Inbred BALB C Microbiology Plasmids - immunology Primates Protein transduction domain Proteins Studies Tissue Fixation Transfection Tumors Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - immunology Viral Fusion Proteins - pharmacology Viral Structural Proteins - pharmacology VP22 |
| title | VP22 enhances antibody responses from DNA vaccines but not by intercellular spread |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T10%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VP22%20enhances%20antibody%20responses%20from%20DNA%20vaccines%20but%20not%20by%20intercellular%20spread&rft.jtitle=Vaccine&rft.au=Perkins,%20Stuart%20D.&rft.date=2005-03-14&rft.volume=23&rft.issue=16&rft.spage=1931&rft.epage=1940&rft.pages=1931-1940&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.10.033&rft_dat=%3Cproquest_cross%3E67471013%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559072948&rft_id=info:pmid/15734065&rft_els_id=S0264410X04007819&rfr_iscdi=true |